InfuSystem (INFU) Stock Price, News & Analysis

Company Overview

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem’s offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions. By integrating connected infusion pumps with data analytics and telehealth platforms, the company enables healthcare providers to monitor therapy progress, optimize patient outcomes and improve staff efficiency. This end-to-end model supports a broad range of IV infusion therapies, including chemotherapy, pain management and antibiotic administration.

Headquartered in St. Petersburg, Florida, InfuSystem was founded in the late 1980s and has grown to serve healthcare facilities across the United States and select international markets. The company is governed by a board of directors and a management team with deep experience in medical device services and healthcare operations. InfuSystem continues to invest in technology and infrastructure to meet evolving regulatory requirements and the shifting landscape of outpatient care.

Key Stats

• Today's Range: $8.37 to $9.03
• 50-Day Range: $8.56 to $10.79
• 52-Week Range: $5.08 to $11.04
• Volume: 347,200 shs
• Average Volume: 132,183 shs
• Market Capitalization: $169.83 million
• P/E Ratio: 140.19
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

InfuSystem Stock Analysis - MarketRank™

InfuSystem scored higher than 83% of companies evaluated by MarketBeat, and ranked 97th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

InfuSystem has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

InfuSystem has a consensus price target of $15.00, representing about 78.4% upside from its current price of $8.41.

Amount of Analyst Coverage

InfuSystem has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 106.67%

Earnings Growth

Earnings for InfuSystem are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InfuSystem is 140.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.13.

Price to Earnings Ratio vs. Sector

The P/E ratio of InfuSystem is 140.19, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.

Price to Book Value per Share Ratio

InfuSystem has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for INFU.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InfuSystem does not currently pay a dividend.

Dividend Growth

InfuSystem does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.29

News Sentiment

InfuSystem has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for InfuSystem this week, compared to 1 article on an average week.

Search Interest

10 people have searched for INFU on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.

MarketBeat Follows

2 people have added InfuSystem to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $18,906.00 in company stock, which represents 0.0111% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, InfuSystem insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,906.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of InfuSystem is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

71.13% of the stock of InfuSystem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:INFU
• Previous Symbol: NYSE:INFU
• CIK: 1337013
• Web: www.infusystem.com
• Phone: (248) 291-1210
• Fax: 800-455-4338
• Employees: 410
• Year Founded: 2005

Price Target and Rating

• Average Price Target for InfuSystem: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +78.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.38
• Trailing P/E Ratio: 140.19
• Forward P/E Ratio: 56.07
• P/E Growth: N/A
• Net Income: $870 thousand
• Net Margins: 1.12%
• Pretax Margin: 2.65%
• Return on Equity: 2.78%
• Return on Assets: 1.41%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.98
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $143.44 million
• Price / Sales: 1.18
• Cash Flow: $0.66 per share
• Price / Cash Flow: 12.79
• Book Value: $2.47 per share
• Price / Book: 3.40

Miscellaneous

• Outstanding Shares: 20,194,000
• Free Float: 19,095,000
• Market Cap: $169.83 million
• Optionable: Optionable
• Beta: 1.49